Skip to main content
  • Report an Adverse Event
  • Locate an MSL
RNAiScience logo
Search Menu
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
  • Log in
  • Sign Up
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

RNAiScience logo
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

  • Report an Adverse Event
  • Locate an MSL
  • Log in
|
  • Sign Up

Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited. 

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

  • AMVUTTRA® (vutrisiran)
  • GIVLAARI® (givosiran)
  • ONPATTRO® (patisiran)
  • OXLUMO® (lumasiran)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis This link is a pdf

Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the APOLLO-B Trial This link is a pdf

Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy This link is a pdf

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis This link is a pdf

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study This link is a pdf

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study This link is a pdf

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B This link is a pdf

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial This link is a pdf

Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program This link is a pdf

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement This link is a pdf

Pagination

  • Previous page
  • 6 of 11
  • Next page

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam
Alnylam logo
RNAI Logo

You are now leaving this site and being directed to a third-party website that is not maintained by Alnylam. Alnylam does not endorse and is not responsible for content or maintenance of third-party websites.

ContinueCancel

RNAI Logo

You are now leaving this site and being directed to another Alnylam website.

ContinueCancel

RNAI Logo

Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.

Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.

Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.

Are you a healthcare professional practicing in the United States?

I confirm I am a US healthcare professional

I am a US payer or healthcare decision maker

I am not a US healthcare professional, or a US payer or healthcare decision maker

I am an Alnylam Team Member

X
Don't miss out!

Sign in to bookmark information and create your personal library

Log in

Don't have an account? Sign up